Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.
Monson KR, Ferguson R, Handzlik JE, Xiong J, Dagayev S, Morales L, Chat V, Bunis A, Sreenivasaiah C, Dolfi S, Tenney DJ, Shao Y, Osman I, Weber JS, Kirchhoff T. Monson KR, et al. Among authors: weber js. Clin Cancer Res. 2024 Oct 1;30(19):4412-4423. doi: 10.1158/1078-0432.CCR-24-0900. Clin Cancer Res. 2024. PMID: 39115425
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS. Gibney GT, et al. Among authors: weber js. Clin Cancer Res. 2015 Feb 15;21(4):712-20. doi: 10.1158/1078-0432.CCR-14-2468. Epub 2014 Dec 18. Clin Cancer Res. 2015. PMID: 25524312 Free PMC article. Clinical Trial.
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.
Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Eroglu Z, et al. Among authors: weber js. Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19. Clin Cancer Res. 2018. PMID: 29674508 Free PMC article. Clinical Trial.
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Joseph RW, et al. Among authors: weber js. Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. Clin Cancer Res. 2018. PMID: 29685882 Free PMC article.
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.
Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R, Berman R, Pavlick AC, Wilson MA, Kirchhoff T, Weber JS, Zhong J, Osman I. Lattanzi M, et al. Among authors: weber js. J Natl Cancer Inst. 2019 Feb 1;111(2):180-188. doi: 10.1093/jnci/djy086. J Natl Cancer Inst. 2019. PMID: 29912415 Free PMC article.
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. Atay C, et al. Among authors: weber js. Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14. Clin Cancer Res. 2019. PMID: 30765391 Free PMC article.
267 results